Cambrdige-based Quotient has announced a significant expansion of its molecular biology services.
According to the company, the move is the result of increasing demand for pharmacogenomic stratification of subjects prior to clinical trial enrolment.
Building on its existing Real-Time PCR instrumentation, Quotient has invested in the latest 384-well format, instrument from Life Technologies, the ViiA7, to support the expansion of services.
John Blackman Northwood, Principal Scientist at Quotient, commented: “Our molecular work dovetails with our gene expression work in metabolism, subject stratification in clinical and biomarker analysis in bioanalysis to create a broader range of services for our clients.”
The lab is also supported by the latest mass spectrometry and immunochemistry technologies to provide in-depth expertise spanning small molecules, biopharmaceuticals, antimicrobials and molecular biology.
